DELIVER

From Wiki Journal Club
Jump to: navigation, search
Solomon SD, et al. "Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction". The New England Journal of Medicine. 2022. :.
PubMedFull textPDF

Clinical Question

In patients with chronic heart failure and left ventricular ejection fraction (LVEF) more than 40%, does an addition of dapagliflozin reduce hospitalization or cardiovasular death?

Bottom Line

In patients with heart failure with preserved ejection fraction or with mildly reduced ejection fraction, dapagliflozin reduces the combined risk of worsening heart failure or cardiovascular death.

Major Points

Several randomized controlled trials have examined the benefits of SGLT2 inhibitors in heart failure patients


Guidelines

Design

Population

Inclusion Criteria

Exclusion Criteria

Baseline Characteristics

Interventions

Primary Outcomes

Secondary Outcomes

Subgroup Analysis

Adverse Events

Criticisms

Funding

Further Reading